42
Participants
Start Date
December 25, 2020
Primary Completion Date
August 3, 2022
Study Completion Date
August 3, 2022
Etrasimod
Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks
Placebo
Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks
Kojunkai Daido Clinic, Nagoya
Kojunkai Daido Hospital, Nagoya
Nagoya City University Hospital, Nagoya
Toyohashi Municipal Hospital, Toyohashi
Tsujinaka Hospital Kashiwanoha, Kashiwa-shi
Ishii Eye Clinic, Nagareyama-shi
Fukuoka University Hospital, Fukuoka
Takimoto Eye Clinic(OCT), Kasuga-shi
Fakuoka Tokushukai Hospital, Kasuga-shi
Gifu University Hospital, Gifu
SUBARU Health Insurance Society Ota Memorial Hospital, Ota-shi
Hiroshima University Hospital, Hiroshima
Asahikawa City Hospital, Asahikawa-shi
NHO Mito Medical Center, Higashiibaraki-gun
Matsumoto Eye Clinic, Toride-shi
NHO Kanazawa Medical Center, Kanazawa
Takamatsu Red Cross Hospital, Takamatsu
Kagawa Prefectural Central Hospital, Takamatsu
JA- Kagoshima Koseiren Hospital (PET/DLCO), Kagoshima
Kagoshima Kouseiren Hospital, Kagoshima
Clinical Pathology Laboratory (Diagnostick center), Kagoshima
Jiaikai Idzuro Imamura Hospital, Kagoshima
Sameshima Eye Clinic (OCT), Kagoshima
Sameshima Hospital, Kagoshima
Japanese Red Cross Kumamoto Hospital, Kumamoto
National Hospital Organization Kyoto Medical Center, Kyoto
Mie University Hospital, Tsu
Mie Prefectural General Medical Center, Yokkaichi-shi
JOHAS Tohoku Rokai Hospital, Sendai
JOHAS Tohoku Rosai Hospital, Sendai
Sendai City Hospital, Sendai
Japan Community Health care Organization Osaka Hospital, Osaka
Saga University Hospital, Saga
St. Luke's International Hospital, Chuo-ku
Showa General Hospital, Kodaira-shi
Kitasato University Kitasato Institute Hospital, Minato-ku
JCHO Tokyo Yamate Medical Center, Shinjuku-ku
Wakayama Medical University Hospital, Wakayama
Lead Sponsor
Arena is a wholly owned subsidiary of Pfizer
INDUSTRY
Pfizer
INDUSTRY